Clinical trials: Pituitary Disease
Acromegaly
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
The morbidity and the mortality in acromegalic patients closely correspond to growth hormone (GH) levels and therefore efficient long-term treatment is important.
- Trial name
- NCT00145405
- Testing
- Lanreotide Autogel and Octreotide LAR
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Odense University Hospital
Pituitary
Clinics and Epidemiology of Pituitary Diseases in Modena Area Population
This is an observational, longitudinal, single-center study. The study is divided in two phases: FIRST PHASE (retrospective): registration of all patients affected by pituitary disorders followed at the Unit of Endocrinology of…
- Trial name
- DataPit (NCT05601141)
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Growth Hormone Deficiency
A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients
The purpose of this study is to assess the long term treatment outcomes of Growth Hormone treatment in patients who are prescribed and treated with Genotropin.
- Trial name
- NCT01947894
- Testing
- Non Interventional Study
- Where
- 12 sites in Sweden
- Volunteers
- 377 people
- Sponsor
- Pfizer
Cushing's Disease
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol.
- Trial name
- BalanCeD (NCT06471829)
- Testing
- Lu AG13909
- Where
- 27 sites in United States, France and 7 more
- Volunteers
- 16 people
- Sponsor
- H. Lundbeck A/S
Female Infertility
Single Dose FSH-GEX™ in Healthy Volunteers
The aim of the current study was the pharmacokinetic and pharmacodynamic characterization of a single dose administration of four doses of FSH-GEX™ in healthy pituitary-suppressed female volunteers, in comparison with two…
- Trial name
- NCT01354886
- Testing
- FSH-GEX™, Gonal-f, Bravelle
- Where
- Netherlands
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Glycotope GmbH
Acromegaly
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
A multicentre, prospective, open label study of acromegalic patients evaluating the efficacy and safety of different dose-intervals of Lanreotide Autogel 120mg according to international standards and compared to previous…
- Trial name
- NCT00444873
- Testing
- lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Ipsen
Fatigue Syndrome, Chronic, Healthy
Study of the Hypothalmic-Pituitary-Adrenal (HPA) Axis and Its Role in Major Depression
Major depression represents a major public health problem worldwide and in the U.S. Fifteen percent of the U.S. population has depression at some point in life (40 million individuals).
- Conditions
- Fatigue Syndrome, Chronic, Healthy, Mood Disorders
- Trial name
- NCT00001479
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Growth Hormone Deficiency, Adult Growth Hormone Deficiency
BELux Children OutcoME During A(@)Dulthood With GHD
Our objective is to evaluate the outcome in adulthood of Belgian and Luxembourgish patients treated with rhGH during childhood for CO-GHD.
- Trial name
- BELCOME@GHD (NCT06694506)
- Testing
- Biological Sample
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Hypopituitarism, Radiotherapy-Induced Hypopituitarism
Improving Survivorship and Health-related Quality of Life in Patients With Primary Brain Tumours
Background: Approximately 480 primary, non-pituitary, brain tumours were diagnosed in Ireland each year between 1994 and 2013. Recent developments in treatment have greatly improved survival for younger patients in the 15-54 age…
- Conditions
- Hypopituitarism, Radiotherapy-Induced Hypopituitarism, Brain Tumor
- Trial name
- NCT06014398
- Testing
- Dynamic testing of Pituitary Function
- Where
- 2 sites in Ireland
- Volunteers
- 50 people
- Sponsor
- Royal College of Surgeons, Ireland
Pituitary Disease
Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
Background: For children with gigantism, too much growth hormone (GH) in the body causes abnormal growth and many other problems. Current treatments often don t work; no medical treatment is approved by FDA.
- Trial name
- NCT03882034
- Testing
- Pegvisomant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Acromegaly
Predictive Factors Study
This is a long term study to evaluate common therapeutic algorithms and possible predictive parameters for Somatuline Autogel treatment in patients with Acromegaly.
- Trial name
- TAPAS (NCT02020499)
- Testing
- Somatuline Autogel® (lanreotide) 60, 90, 120 mg.
- Where
- 6 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Ipsen
Acromegaly
Lanreotide Levels in Acromegaly
Recently lanreotide (a somatostatin analog) has come into the US marketplace as a commercially available medication approved by the FDA for the treatment of acromegaly.
- Trial name
- NCT00916916
- Testing
- Blood draw
- Where
- United States
- Sponsor
- Cedars-Sinai Medical Center
Acromegaly
Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly
OBJECTIVES: I. Determine whether release of endogenous growth hormone (GH)-releasing hormone is involved in GH responses to clonidine, pyridostigmine, levodopa, arginine, GH-releasing peptide, insulin-induced hypoglycemia, and…
- Trial name
- NCT00004332
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Acromegaly
Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly
To investigate the 60 month impact of surgery and somatostatin analogues (SSA) on glucose metabolism in acromegaly we will analyzed data from 100 patients with acromegaly according with different treatments (group A=with SSA…
- Trial name
- GLUSSA (NCT00703079)
- Testing
- Octreotide-LAR or lanreotide, Transsphenoidal adenomectomy
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Federico II University
Placenta Previa
Tranexamic Acid vs Vasopressin in Placenta Previa Trial
Placenta previa is a major obstetric condition associated with increased risk of excessive blood loss during cesarean section, leading to maternal morbidity and mortality.
- Trial name
- TXA-VASO-PP (NCT07423156)
- Testing
- Group A: Tranexamic acid, Group B: Vasopressin
- Where
- Pakistan
- Volunteers
- 58 people
- Sponsor
- Allama Iqbal Medical College
Inappropriate ADH Syndrome, Hyponatremia
Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
To assess the efficacy of SR121463B in correcting hyponatremia in patients with syndrome of inappropriate antidiuretic secretion (SIADH).To assess the long-term efficacy of SR121463B in maintaining normal levels of serum sodium…
- Trial name
- SIADH (NCT00264927)
- Testing
- SR121463B
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 77 people
- Sponsor
- Sanofi
Adult Growth Hormone Deficiency
A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency
This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).
- Trial name
- NCT01909479
- Testing
- MOD-4023
- Where
- Israel
- Volunteers
- 202 people
- Sponsor
- OPKO Health, Inc.
Healthy
A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens
This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy, reproductive-aged women using three different regimens of oral contraceptives (OCs).
- Trial name
- NCT00117273
- Testing
- Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Duramed Research
Syndrome of Inappropriate ADH (SIADH) Secretion, Hyponatremia
Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
The study is designed to assess the efficacy of an investigational drug called SR121463B (vasopressin receptor antagonist) in the treatment of low levels of sodium in the blood associated with the Syndrome of Inappropriate…
- Trial name
- NCT00032734
- Testing
- satavaptan (SR121463B)
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 35 people
- Sponsor
- Sanofi
Inappropriate ADH Syndrome, Hyponatremia
Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
To determine the long-term safety and tolerability of SR121463B in patients with syndrome of inappropriate antidiuretic secretion (SIADH).
- Trial name
- SIADH Safety (NCT00264914)
- Testing
- SR121463B
- Where
- 11 sites in United States, Australia and 9 more
- Volunteers
- 57 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.